Adaptive Biotechnologies (ADPT) EPS (Basic) (2018 - 2026)

Adaptive Biotechnologies has disclosed EPS (Basic) across 9 years of filings, most recently posting -$0.13 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at -$0.13, up 35.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.33 (up 65.26% YoY), and the FY2025 annual result was -$0.39, up 63.89% from the prior year.
• EPS (Basic) came in at -$0.13 for Q1 2026 at Adaptive Biotechnologies, down from -$0.09 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.06 in Q3 2025 to a low of -$0.48 in Q4 2023.
• The 5-year median for EPS (Basic) is -$0.31 (2024), against an average of -$0.27.
• Across the five-year window, EPS (Basic) tumbled 71.43% in 2023 and surged 127.27% in 2025, its largest moves.
• Adaptive Biotechnologies' EPS (Basic) stood at -$0.28 in 2022, then plunged by 71.43% to -$0.48 in 2023, then soared by 54.17% to -$0.22 in 2024, then soared by 59.09% to -$0.09 in 2025, then tumbled by 44.44% to -$0.13 in 2026.
• The last three EPS (Basic) figures came in at -$0.13 (Q1 2026), -$0.09 (Q4 2025), and $0.06 (Q3 2025), per Business Quant data.